CareDx, Inc.
CDNADiagnostics & Research
$71.52−0.85%As of Oct 29vs prior close
- Market cap
- $3.7B
- P/E (TTM)
- 28.7×
- P/E (FY1)
- 59.7×
- From 52W high
- −0.85%
- EPS (LTM)
- $2.39
- Revenue (LTM)
- $497.4M
- Net margin
- 25.86%
- Dividend yield
- 0.00%
Nomior Score
72
Emerging BreakoutSpeculativeTop 8% of the scored universe
Growth57
Quality72
Value45
Momentum100
Resilience42
Growth
+28.19%revenue a year over 9 fiscal years
FY16 $40.6MLTM $497.4M
Connections
Revenue to profitQ3 FY26
14% of revenue became net profit, up 12 pts on a year.
Latest resultsThird Quarter 2026
- Revenue
- $139 million
- Net income
- $19 million
- Revenue outlook
- $520 million to $530 million
Revenue grew strongly year over year, driven mainly by Testing Services, including contributions from the NavDx acquisition, and by Patient and Digital Solutions. GAAP net income and adjusted EBITDA both improved sharply, helped by higher gross profit and disciplined operating expense management. The company raised its full-year revenue and adjusted EBITDA guidance.
Who owns it
2funds, 1 tracked portfolio